| Biomarker ID | 1725 |
| PMID | 30777394 |
| Year | 2019 |
| Biomarker | miR-24+miR-30c+ Methylation Status of CRIP3 |
| Biomarker Basis | Expression Based+ Methylation Based |
| Biomolecule | miRNA + DNA (Gene) |
| Source | Urine |
| Subjects | Humans |
| Regulation | Increased in shorter BCR-free survival |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: Univariate: 2.166 (95% CI: 1.22-3.847); Multivariate: 1.992 (95% CI: 1.131-3.51) |
| Effect on Pathways | Pathway include: KRAS pathway |
| Experiment | Reclassification (Progression Vs No Progression) |
| Type of Biomarker | Prognostic |
| Cohort | 109 patients with Prostate Cancer were selected for the study. Out of which 23 patients were reclassified: |
| Senstivity | 81% |
| Specificity | 59.7% |
| AUC | 0.708 (95% CI: 0.586-0.830) |
| Accuracy | NA |
| Level Of Significance | Univariate: p=0.008; Multivariate: p=0.017 |
| Method Used | qPCR-based MethyLight assay |
| Clinical | No |
| Remarks | Patients were considered reclassified if they experienced Gleason Grade increase on repeat biopsy |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |